Keshelava Viktor Vladimirovich

Biography

 Main specialization: Oncologist  Clinic: Clinical diagnostic center MEDSI at Belorussian  Scientific degree / Category: Professor / Doctor of Medical Sciences  Professional achievements and experience:    For more than 30 years he worked in the leading oncological centers in Moscow, holding positions from a junior researcher to the head of the department of oncology.     Scientific and practical activities are related to the experimental development and clinical introduction of medicinal complexes in oncology, the development of methodological approaches to the diagnosis of surgical, combined and complex treatment and medical rehabilitation of cancer patients. Over the past 10 years, as part of interstate and international research, he has been dealing with the problem of cancer biotherapy, including the development of vaccines, both for prevention and for treatment. All these problems were studied in the framework of interstate and international research. At present, the results of multicenter studies of the use of viruses, vaccines, bacteria, immunomodulators, chemotherapeutics in the mode of metronome therapy in complex immunotherapy for the treatment of generalized forms of kidney, prostate, breast, cervix, ovaries, colorectal cancer, etc. These patients with multiple growing metastases are resistant to radiation and chemotherapy. According to the pilot clinical studies, the use of immunotherapy is 15% more effective than the standard chemotherapeutic effect. As a result of treatment, an increase in survival, a high level of objective response, an improvement in the quality of life, good tolerability, safety, and a dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. These are patients with multiple growing metastases that are resistant to radiation and chemotherapy. According to the pilot clinical studies, the use of immunotherapy is 15% more effective than the standard chemotherapeutic effect. As a result of treatment, an increase in survival, a high level of objective response, an improvement in the quality of life, good tolerability, safety, and a dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. These are patients with multiple growing metastases that are resistant to radiation and chemotherapy. According to the pilot clinical studies, the use of immunotherapy is 15% more effective than the standard chemotherapeutic effect. As a result of treatment, an increase in survival, a high level of objective response, an improvement in the quality of life, good tolerability, safety, and a dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. According to the pilot clinical studies, the use of immunotherapy is 15% more effective than the standard chemotherapeutic effect. As a result of treatment, an increase in survival, a high level of objective response, an improvement in the quality of life, good tolerability, safety, and a dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. According to the pilot clinical studies, the use of immunotherapy is 15% more effective than the standard chemotherapeutic effect. As a result of treatment, an increase in survival, a high level of objective response, an improvement in the quality of life, good tolerability, safety, and a dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. improved quality of life, good tolerability, safety, and the dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad. improved quality of life, good tolerability, safety, and the dominant role of immunotherapy in the treatment of patients with terminal cancer. The proposed methods of immunotherapy are based on the use of a huge arsenal of clinical, molecular - biological, genetic studies, taking into account the latest scientific achievements and advanced techniques and are of sufficient interest both in Russia and abroad.     Research results Keshelava V.V. were reflected in 5 monographs and 150 publications in domestic and foreign journals. The research materials were presented at international and republican congresses, conferences, symposia. Keshelava V.V. 55 patents (inventions of the USSR, patents of the Russian Federation and foreign patents) are offered and protected.     At present, it is necessary to note the presence of a large number of medical centers in France, England, Australia, the USA, Canada, Germany, Latvia, China, Israel and other countries dealing with the problem of cancer immunotherapy.  

Research Interest

 Oncology